Close Menu

NEW YORK (360Dx) — NuView Life Sciences has signed an agreement to evaluate its NV-VPAC1 urogenital cancer test on Aperture Bio's screening platform, the company announced today.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.